252943-80-9 Usage
Description
1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is a chemical compound with the molecular formula C10H13N7. It is a guanidine derivative that contains a cyanopyridine group and an aminoethyl group attached to a guanidine moiety. 1-(2-(5-cyanopyridin-2-ylaMino)ethyl)guanidine is commonly used in medicinal chemistry research for its potential pharmacological properties.
Uses
Used in Pharmaceutical Research:
1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is used as a research compound for its potential antimicrobial properties and as a potential treatment for various diseases such as cancer and neurodegenerative disorders. Its unique chemical structure and properties make it a valuable compound for further research and development in the field of pharmaceuticals.
Used in Antimicrobial Applications:
In the medical industry, 1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is used as an antimicrobial agent to combat various infections. Its specific mode of action and effectiveness against different types of pathogens are currently under investigation.
Used in Drug Development:
1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is also used as a starting material or a building block in the development of new drugs with therapeutic applications. Its versatile chemical structure allows for the creation of novel compounds that may have improved pharmacological properties or reduced side effects compared to existing treatments.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is used as a compound for studying its potential pharmacological properties. This includes understanding its interactions with biological targets, such as enzymes or receptors, and evaluating its efficacy and safety as a potential therapeutic agent.
Overall, 1-(2-(5-cyanopyridin-2-ylamino)ethyl)guanidine is a promising compound with various applications in the pharmaceutical and medical industries, including antimicrobial treatments, drug development, and medicinal chemistry research. Its potential uses are still being explored, and further studies may reveal additional applications and benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 252943-80-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,9,4 and 3 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 252943-80:
(8*2)+(7*5)+(6*2)+(5*9)+(4*4)+(3*3)+(2*8)+(1*0)=149
149 % 10 = 9
So 252943-80-9 is a valid CAS Registry Number.
252943-80-9Relevant articles and documents
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3
Wagman, Allan S.,Boyce, Rustum S.,Brown, Sean P.,Fang, Eric,Goff, Dane,Jansen, Johanna M.,Le, Vincent P.,Levine, Barry H.,Ng, Simon C.,Ni, Zhi-Jie,Nuss, John M.,Pfister, Keith B.,Ramurthy, Savithri,Renhowe, Paul A.,Ring, David B.,Shu, Wei,Subramanian, Sharadha,Zhou, Xiaohui A.,Shafer, Cynthia M.,Harrison, Stephen D.,Johnson, Kirk W.,Bussiere, Dirksen E.
, p. 8482 - 8514 (2017/11/03)
In an effort to identify new antidiabetic agents, we have discovered a novel family of (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3). We developed efficient synthetic routes to explore a wide variety of substitution patterns and convergently access a diverse array of analogues. Compound 1 (CHIR-911, CT-99021, or CHIR-73911) emerged from an exploration of heterocycles at the C-5 position, phenyl groups at C-4, and a variety of differently substituted linker and aminopyridine moieties attached at the C-2 position. These compounds exhibited GSK3 IC50s in the low nanomolar range and excellent selectivity. They activate glycogen synthase in insulin receptor-expressing CHO-IR cells and primary rat hepatocytes. Evaluation of lead compounds 1 and 2 (CHIR-611 or CT-98014) in rodent models of type 2 diabetes revealed that single oral doses lowered hyperglycemia within 60 min, enhanced insulin-stimulated glucose transport, and improved glucose disposal without increasing insulin levels.
